XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 32.93

+2.9%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bluegreen who wrote (13685)	5/27/2000 3:40:00 PM
From: Cacaito	Read Replies (1) of 17367

Blue, no place for bpi in treatment of O157:H7. The just publish study is clear: no antibiotic,no killing is better to avoid HUS, once establish is too late. Similar observation was done decades ago about Salmonella and avoidance of antibiotic has being the mainstay of treatment, same for diarrhea and antibiotics avoidance equal less problem, now it seems that less HUS too. One could not use even a cheap $100 dose bpi for this problem when peptobismol (couple of teaspoon/tablespoon) will do the job. Avoidance of killing is precisely the job. Avoidance of enviromental factors, ie feed cows grass,not grain is the job. xoma will give data on bpi when is no longer worth to know, when they suck out the max out of financing the hope, no financing possible with the plain truth:FAILURE.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next